Clinical Trial Update: Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial [Phase 3]

View source ↗

Summary

A Phase 3 randomized multicenter trial is evaluating methotrexate as a steroid-sparing treatment for idiopathic retroperitoneal fibrosis, with perianeurysmal re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Retroperitoneal Fibrosis
• Perianeurysmal Retroperitoneal Fibrosis
• Periaortitis

Drugs mentioned

• METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: University of Parma | Conditions: Idiopathic Retroperitoneal Fibrosis, Perianeurysmal Retroperitoneal Fibrosis | Phase 3 | Status: UNKNOWN